Study Finds Cost-sharing Assistance Programs Can Save Patients Thousands While Leading to Improved Adherence and Health Outcomes.
According to a recent analysis by IQVIA, chronically ill patients using cost-sharing assistance saved hundreds to thousands of dollars on [...]
How Can Excessive Price Increases Be Better Regulated?
Much of the overall spending on prescription drugs in the United States can be attributed to price increases, resulting in [...]
What is the Most Effective Way to Navigate Pricing Models for COVID-19 Innovations?
Preliminary clinical benefit information is translated into longer-term health benefit and economic value through pricing models, making them invaluable for [...]
Value of a QALY for France
Until now, no cost-effectiveness threshold (CET) has been officially proposed in France to qualify incremental cost-effectiveness ratios (ICERs). To address [...]
How Did Pharmaceutical Policy Reform Change the Healthcare Landscape in China?
China’s pharmaceutical market is second only to the United States valued at $137 billion (USD). Fueling Growth has been fueled [...]
Aetna and Cleveland Clinic Launch Co-branded Health Plan.
The joint Aetna Whole Health – Cleveland Clinic plan, available in NE Ohio, utilizes Cleveland Clinic's providers to provide a [...]
[Presentation] IMPACCT: Real World Evidence–Use of Real World Data Outside of Traditional Comparative Effectiveness Research
[Presentation] IMPACCT: Real World Evidence--Use of Real World Data Outside of Traditional Comparative Effectiveness Research by Ravi Iyer, Director GHEOR, [...]
[Presentation] IMPACCT: Real World Evidence–The Rile of Real World Evidence (RWE) in a Comprehensive Product Evidence Generation Plan
[Presentation] IMPACCT: Real World Evidence--The Rile of Real World Evidence (RWE) in a Comprehensive Product Evidence Generation Plan by Cathy [...]
[Presentation] IMPACCT: Real World Evidence–Lessons Learned From The Development And Implementation of an Integrated Data And Evidence Strategy
IMPACCT: Real World Evidence--Lessons Learned From The Development And Implementation of an Integrated Data And Evidence Strategy by Tony Hebden [...]
Cost-Sharing Waivers for COVID-19 Treatment Are Expiring
Cost-sharing waivers for COVID-19 treatment are due to expire in the upcoming months. Approximately 88% in individual and fully insured [...]
[Webinar] Value Assessment in the Age of COVID-19: Meeting the Challenges
An important discussion is developing around Value Assessment (VA) and Health Technology Assessment (HTA) as COVID-19 intensifies challenges to effectively [...]
Teva Pharmaceuticals Stock Plunges 15.4%
Teva Pharmaceutical stands accused of defrauding Medicare using a kickback scheme to boost sales of Copaxone, prompting the US government [...]
[Video Chat] A Pandemic Means Society Needs Information Fast. Can Researchers Provide It?
Don't miss Stat's upcoming video chat on Thursday, Sept. 17 at 1 p.m. ET / 10 a.m. PT: Getting real [...]
[PODCAST] Open Access: Opportunities and Challenges
As the principles of open science become more widely adopted, open access publishing is an increasingly debated topic. Join International [...]
Payer Contact in a “Contactless” World: Achieving Early Engagement
The COVID-19 pandemic has prompted life sciences organizations to quickly pivot their payer strategic approach and tactical implementation. Engaging payers [...]
How is Patient-Centered Outcomes Research Institute (PCORI) Contributing to The Fight Against COVID-19?
In response to the COVID-19 pandemic, the Patient-Centered Outcomes Research Institute (PCORI) has approved over $20 million in funding for [...]
Highmark and UCB Partner on Outcomes-based Contract for CIMZIA
Highmark has entered an outcomes-based agreement with UCB, Inc. for CIMZIA® (certolizumab pegol), UCB’s tumor necrosis factor blocker prescribed for [...]
Study Finds That Less Than 20% of Medicare Spending is Value-based
Boston-based health insurance company Coverys found that less than 20% of Medicare spending is value-based. In order to meet future [...]
How Are the U.S. Postal Service’s Woes Affecting Prescriptions?
There is increasing concern among physicians and policymakers that uncertainty concerning the fate of the U.S. Postal Service could delay [...]
How Can Chief Outcomes Officers Transform the C-Suite?
Improving outcomes, lowering costs, and increasing satisfaction are universal goals that few health care organizations or consumers feel they have [...]
Pharma14 adds South Korea to Global Medicine and Pricing Database
The pharmaceutical market in South Korea is undergoing rapid expansion and expected to reach more than US$ 21 billion by [...]
The Professional Society for Health Economics and Outcomes Research (ISPOR) Now Offers Renowned Short Course Program Virtually
ISPOR’s is offering the following virtual courses through its renowned short course program: September [...]
Course offering: Introduction to Medical Affairs in Medicines Development
Don’t miss out on this exciting new course covering the fundamentals of Medicines Development and how Medical Affairs functions bring [...]
How Does Consolidation Drive Prices?
Why do Americans spend so much on healthcare? According to a recent literature review, part of the reason may be [...]
Kamala Harris Is No Friend to Pharma
Vice presidential nominee Kamala Harris is not exactly the centrist the media are making her out to be—especially when it [...]